WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H464126
CAS#: 1830320-32-5
Description: RB394 is a dual sEH/PPARγ modulator.
Hodoodo Cat#: H464126
Name: RB394
CAS#: 1830320-32-5
Chemical Formula: C21H22F3NO4
Exact Mass: 409.15
Molecular Weight: 409.410
Elemental Analysis: C, 61.61; H, 5.42; F, 13.92; N, 3.42; O, 15.63
Synonym: RB394; RB 394; RB-394;
IUPAC/Chemical Name: 2-(4-((4-methoxy-2-(trifluoromethyl)benzyl)carbamoyl)benzyl)butanoic acid
InChi Key: JUYLDNKPEWYVEB-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H22F3NO4/c1-3-14(20(27)28)10-13-4-6-15(7-5-13)19(26)25-12-16-8-9-17(29-2)11-18(16)21(22,23)24/h4-9,11,14H,3,10,12H2,1-2H3,(H,25,26)(H,27,28)
SMILES Code: COC1=CC(C(F)(F)F)=C(CNC(C2=CC=C(CC(C(O)=O)CC)C=C2)=O)C=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, DMF, and ethanol
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO, DMF, and ethanol
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| Soluble in DMSO | 0.0 | 100.00 |
The following data is based on the product molecular weight 409.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Hartmann M, Bibli SI, Tews D, Ni X, Kircher T, Kramer JS, Kilu W, Heering J, Hernandez-Olmos V, Weizel L, Scriba GKE, Krait S, Knapp S, Chaikuad A, Merk D, Fleming I, Fischer-Posovszky P, Proschak E. Combined Cardioprotective and Adipocyte Browning Effects Promoted by the Eutomer of Dual sEH/PPARγ Modulator. J Med Chem. 2021 Feb 23. doi: 10.1021/acs.jmedchem.0c02063. Epub ahead of print. PMID: 33620196.
2: Stavniichuk A, Hye Khan MA, Yeboah MM, Chesnik MA, Jankiewicz WK, Hartmann M, Blöcher R, Kircher T, Savchuk O, Proschak E, Imig JD. Dual soluble epoxide hydrolase inhibitor/PPAR-γ agonist attenuates renal fibrosis. Prostaglandins Other Lipid Mediat. 2020 Oct;150:106472. doi: 10.1016/j.prostaglandins.2020.106472. Epub 2020 Jun 20. PMID: 32569747.
3: Hye Khan MA, Kolb L, Skibba M, Hartmann M, Blöcher R, Proschak E, Imig JD. A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes. Diabetologia. 2018 Oct;61(10):2235-2246. doi: 10.1007/s00125-018-4685-0. Epub 2018 Jul 21. PMID: 30032428; PMCID: PMC6563928.
